More data from onvansertib's phase 2 study fail to convince.
ApexOnco Front Page
Recent articles
NT-125 is discontinued, while two key Datroway readouts are delayed.
Luminice-203 yields its first topline data, but where are all the patients?
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
Pfizer moves to take PF-07934040 into its first clinical trial.
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.
Supply continues to cause headaches for radiopharmaceutical developers.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.